Schering and Sepracor to produce Clarinex-D generics

HYDERABAD, India Dr. Reddy's has entered into agreements with Schering and Sepracor that will allow it to manufacture and market generic versions of the 12-hour and 24-hour formulations of the prescription antihistamine Clarinex-D, Dr. Reddy's announced last week.

As part of the agreement, Dr. Reddy's will get six months' market co-exclusivity when it starts to market its versions of Clarinex-D(desloratadine) in 2012. Six months later, it will begin marketing its generic version of Clarinex tablets in the 5 mg strength. 

The agreements resolve patent infringement suits that Schering and Sepracor filed against Dr. Reddy's in the United States District Court for the District of New Jersey.

Clarinex products had sales of $362 million in 2007.